BiosparQ B.V. is a privately-held in vitro diagnostics company dedicated to provide healthcare professionals with a unique solution for rapid diagnostics of infectious diseases that improves patient outcomes, lowers healthcare costs and helps turn back Antimicrobial Resistance (AMR).
BiosparQ has focused its efforts on research into and the development of the Cirrus D20 medical diagnostic platform, based on proprietary DigiTOF® technology. This technology enables direct analysis of patient samples using a Single-cell MALDI-TOF approach. DigiTOF® was initially developed by the TU Delft (Prof. J. Marijnissen et.al.) in co-operation with the Dutch Contract Research Organization TNO, under contracts of the US and Dutch Ministries of Defense in the early 2000s.
After incorporation and closing of seed funding rounds in 2009, BiosparQ began as a virtual company based in Delft. In 2012, a substantial series A round was closed, which enabled BiosparQ to grow into a fully integrated company. All DigiTOF® assets from TU Delft / TNO was acquired (Patent portfolio and Cirrus D20 prototype hard- and software). It was decided move to the Leiden Bioscience Park, renting well equipped laboratories and offices from Biopartner foundation.
In 2016 a series B funding round was closed and in 2018 the company was granted an Innovation Credit by the Dutch government, enabling the company to mature the Cirrus D20 platform and develop, validate and certify the first applications.
Since 2009, the BiosparQ established an international network of clinical partners that support the company to create the applications pipeline. Several (inter)national subsidies were granted to the BiosparQ and its partners. In 2018, a supply chain consisting of high-tech suppliers was created to prepare for production qualification.
